ABBVIE INC. (ABBV)
Healthcare – PHARMACEUTICAL PREPARATIONS
- CEO
- Robert A. Michael
- Headquarters
- United States
- Employees
- 57,000
- Market Cap
- $465.2B
About ABBVIE INC.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
SentiSense also tracks daily options readings for ABBVIE INC.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
ABBVIE INC. stock analysis, sentiment tracking, and market intelligence on SentiSense.